Post Market Study of the 3DKnee™ With E-plus Insert (e-plus)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the use and efficacy of the 3DKnee™ System using Vitamin E UHMWPE tibial inserts for total knee replacement surgery.
| Condition | Intervention |
|---|---|
|
Osteoarthritis Traumatic Arthritis Total Knee Joint Prosthesis |
Device: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prospective Multicenter Open Label Study Examining the Mid- and Long-term Safety and Efficacy of the 3DKnee™ System With Vitamin E UHMWPE Tibial Inserts (3DKnee™ With E-plus Insert) |
- Knee Society Score Evaluation [ Time Frame: 2 year ] [ Designated as safety issue: No ]The (American) Knee Society Score has both an objective and a functional component. The objective score takes into account pain, flexion, stability, alignment, extension lag and flexion contracture and is calculated on a total possible score of 100. The function portion of the KSS, also calculated out of a total of 100 possible points, gives points for walking distance and stair climbing and deducts points for walking aids. Overall success will be defined as a KSS score ≥ 80 at two years.
- Number of Participants With Radiologic Failure of Device [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]Radiolucencies have been defined as two types, with one type being more common than the other. In the case of physiologic radiolucency, which is the most common type of radiolucency seen, there is a narrow line present that is well-defined around the prosthesis. This line is surrounded by a radio-dense line and tends to consolidate (disappear) within the first year. The second type of radiolucency, the pathologic radiolucency, is rarer and is associated with loosening and infection. It is a progressive, poorly defined radiolucency that is more than 2 mm thick and without a radiolucent line
- Change in Knee Society Score from pre-surgery to 10 years [ Time Frame: 10 year ] [ Designated as safety issue: No ]The Knee Society Score includes a knee rating and function score. This evaluation covers the knee rating score with three main parameters of pain, stability and range of motion and that flexion contracture, extension lag and misalignment should be dealt with as deductions. Thus, 100 points will be obtained by a well-aligned knee with no pain, 125 degrees of motion, and negligible anteroposterior and mediolateral instability. 50 points are allotted for pain, 25 for stability, and 25 for range of motion. Grading for KS Score: Excellent (90-100), Good (80-90), Fair (70-79) and Poor (<70).
- Change in WOMAC Osteoarthritis Index from pre-surgery to 10 years [ Time Frame: 10 year ] [ Designated as safety issue: No ]The Western Ontario McMaster Arthritis Index is a set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip. It can be self-administered. It assesses the pain, joint stiffness, physical, social & emotional function of a person with osteoarthritis in determining the overall level of disability.
- Change in Oxford Knee Score from pre-surgery to 10 years [ Time Frame: 10 year ] [ Designated as safety issue: No ]The Oxford Knee Score (OKS) is a patient-based outcomes measure consisting of 12 questions that is sensitive, simple and validated. It is based on a maximum score of 48.
| Estimated Enrollment: | 300 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | June 2024 |
| Estimated Primary Completion Date: | June 2016 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
3DKnee™ with e-plus Insert
Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
|
Device: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
|
Detailed Description:
Total knee replacement surgery is widely accepted as effective treatment for degenerative joint disease (DJD), osteoarthritis and rheumatoid arthritis. Relief of patient pain and return of mobility are the primary goals that can be accomplished by this surgery. Currently available prosthetic designs accomplish these goals and the surgery has been defined as one of the most successful operations available to improve the quality of life for patients with DJD. This study will evaluate subjects who are candidates for a total knee replacement and meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE).
Eligibility| Ages Eligible for Study: | 40 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects must be diagnosed with either osteoarthritis or traumatic arthritis and be candidates for a primary total knee arthroplasty. They must also meet the indications for use for the 3DKnee system with the vitamin E tibial insert.
Inclusion Criteria:
- Subject must be a candidate for a total primary knee replacement.
- Subject must have knee joint disease related to degenerative joint disease, including osteoarthritis or traumatic arthritis
- Subject has a BMI ≤ 35.00 kg/m2
- Subject is likely to be available for evaluation for the duration of the study
- Subject is able and willing to sign the informed consent and follow study procedures
- Subject is not pregnant
- Subject must be between age 40 and age 75 at the time of consent
Exclusion Criteria:
- Subject has had a prior total or uni-knee replacement on this knee in the past (no revisions allowed in study)
- Subject has avascular necrosis of the femoral condyles, post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy, moderate valgus, varus, or flexion deformities or rheumatoid arthritis
- Subject has an active cancer or is a survivor for <5 years except for squamous cell or basal cell skin cancer
- Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol
- Subject is currently a documented substance abuser (alcohol or other addictions)
- Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic
- Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity
- Subject has a BMI > 35.00 kg/m2
- Subject has loss of ligamentous structures
- Subject has high levels of physical activity and is unwilling to modify levels of physical activity commensurate with recommendations
- Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)
- Subject is a prisoner
- Subject is pregnant
- Subject has known materials sensitivity (to metals)
- Subject is younger than 40 years (<40) or older than 75 years (>75) at the time of consent
Contacts and Locations| Contact: Derek E Coulter, BS | 512-834-6284 | derek.coulter@djoglobal.com |
| United States, Alabama | |
| USA Orthopedics | Recruiting |
| Mobile, Alabama, United States, 36693 | |
| Principal Investigator: Albert W. Pearsall IV, M.D. | |
| United States, Arizona | |
| Valley Bone & Joint Specialists | Recruiting |
| Mesa, Arizona, United States, 85206 | |
| Principal Investigator: Salvatore G Lacognata, D.O. | |
| United States, California | |
| Orthopaedic Surgery Specialists | Recruiting |
| Burbank, California, United States, 91505 | |
| Principal Investigator: Shahan V Yacoubian, M.D. | |
| Sub-Investigator: Stephan V. Yacoubian, M.D. | |
| United States, Colorado | |
| Colorado Orthopedic Consultants, PC | Recruiting |
| Englewood, Colorado, United States, 80110 | |
| Principal Investigator: Jeffrey A. Arthur, D.O. | |
| Sub-Investigator: Philip A. Stull, M.D. | |
| Sub-Investigator: Stephen D. Lindenbaum, M.D. | |
| Sub-Investigator: Peter L. Weingarten, M.D. | |
| Sub-Investigator: Stewart K. Weinerman, M.D. | |
| United States, Florida | |
| Coastal Orthopedics & Sports Medicine | Recruiting |
| Bradenton, Florida, United States, 34209 | |
| Principal Investigator: John R. Ayres, M.D. | |
| Institute for Orthopaedic Surgery and Sports Medicine | Recruiting |
| Fort Myers, Florida, United States, 33919 | |
| Principal Investigator: George D. Markovich, M.D., FACS | |
| Mercy Hospital | Recruiting |
| Miami, Florida, United States, 33133 | |
| Principal Investigator: Wilfredo P. Amaya, M.D. | |
| Florida Orthopaedic Institute | Recruiting |
| Temple Terrace, Florida, United States, 33637 | |
| Principal Investigator: Michael Miranda, D.O. | |
| United States, Maryland | |
| OrthoMaryland | Recruiting |
| Baltimore, Maryland, United States, 21209 | |
| Principal Investigator: Barry J. Waldman, M.D. | |
| United States, Missouri | |
| St. Peter's Bone & Joint Surgery | Recruiting |
| St. Peters, Missouri, United States, 63376 | |
| Principal Investigator: John W. McAllister, M.D. | |
| United States, New Mexico | |
| New Mexico Orthopedics | Recruiting |
| Albuquerque, New Mexico, United States, 87106 | |
| Principal Investigator: Joshua T. Carothers, M.D. | |
| Sub-Investigator: Krishna R. Tripuraneni, M.D. | |
| United States, New York | |
| NYU Hospital for Joint Diseases | Recruiting |
| New York, New York, United States, 10003 | |
| Principal Investigator: Claudette LaJam, M.D. | |
| United States, Texas | |
| Texas Institute for Hip and Knee Surgery | Not yet recruiting |
| Austin, Texas, United States, 78751 | |
| Contact: Kaitlin Brangan | |
| Principal Investigator: David A. Dodgin, M.D. | |
| Sub-Investigator: Eric M. Heinrich, M.D. | |
More Information
No publications provided
| Responsible Party: | Encore Medical, L.P. |
| ClinicalTrials.gov Identifier: | NCT01551472 History of Changes |
| Other Study ID Numbers: | PS-706 |
| Study First Received: | March 8, 2012 |
| Last Updated: | January 4, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Arthritis Osteoarthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Vitamin E Alpha-Tocopherol Tocopherols Tocotrienols |
Vitamins Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 16, 2013